FENC

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc. (FENC) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B (3.2) A (4.2) B (3.4) B (3.5) C+ (2.6) B (3.4)
2026-11-04 B (3.2) A (4.2) B (3.4) B+ (3.7) C+ (2.7) B (3.4)
2026-10-28 B (3.2) A (4.2) B (3.3) B+ (3.7) C+ (2.7) B (3.4)
2026-10-21 B (3.2) A (4.2) B (3.3) B+ (3.5) C+ (2.6) B (3.4)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe